Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 936 trials

FB301: First-in-Human Study

We are testing a new medication called FB301 in healthy women to evaluate its safety and how it is processed in the body. This study aims to gather important information for future research.

InfertilitySafety phase (I)Gynecology and Obstetrics

Rheumatoid Arthritis: ABO21009 Treatment Study

We are testing a new treatment called ABO21009 in healthy volunteers and patients with rheumatoid arthritis. The goal is to see how it compares to a placebo in terms of safety and effects.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Advanced Solid Tumors: PM54 Treatment Study

We are testing a new drug called PM54 in patients with advanced solid tumors to see how safe it is and how it works. This study aims to explore new treatment options for those with limited choices.

Selected Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Solid Tumors: YL201 Treatment Study

We are investigating a new treatment called YL201 for patients with advanced solid tumors. The goal is to see how effective and safe it is compared to current options.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Asthma Treatment: JNJ-95597528

We are testing a new medication to see if it is safe and how it works in people with mild to moderate asthma. This study will help us understand its effects compared to a placebo.

Mild to Moderate Asthma1-2 yearsSafety phase (I)Internal MedicinePulmonology

Glioblastoma: Radiodynamic Therapy with 5-Aminolevulinic Acid

We are testing a new treatment combining radiodynamic therapy and 5-Aminolevulinic acid for patients with a first recurrence of glioblastoma. The goal is to find the highest safe dose and ensure it can be tolerated.

Recurrent Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Macitentan Dosing Study in Healthy Adults

We are comparing the effects of two doses of Macitentan on blood vessel function and heart health in healthy participants. This research may help us understand how different doses impact the body.

Pulmonary Arterial Hypertension1-2 yearsSafety phase (I)Cardiology

Daratumumab for Monoclonal Gammopathy of Renal Significance

We are investigating how effective Daratumumab is for patients with Monoclonal Gammopathy of Renal Significance in Finland. This study aims to understand its potential benefits for kidney health.

Monoclonal Gammopathy of Renal Significance (MGRS)Safety phase (I)HematologyNephrology

CAR T Cell Therapy for Severe Autoimmune Diseases

We are testing a new treatment using engineered immune cells for people with severe autoimmune diseases that haven't improved with standard therapies. This study aims to see if this approach can help manage their condition.

Idiopathic Inflammatory MyopathySystemic Lupus ErythematosusRheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Knee Cartilage Damage: UC-MSC Treatment

We are studying a new treatment using stem cells from umbilical cord tissue for people with cartilage damage in the knee. The trial aims to evaluate the safety and effectiveness of this approach.

Knee Cartilage Defect1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Advanced NSCLC: Roginolisib with Dostarlimab

We are studying a new treatment combination for patients with advanced non-squamous lung cancer who have not responded to standard therapies. The trial will evaluate safety and early signs of effectiveness.

Advanced Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Solid Cancers: NI-1801 Antibody Study

We are testing a new antibody treatment for patients with solid cancers to see how well it works alone and with other therapies. This study aims to understand its safety and potential benefits.

Malignant Solid Tumor3-6 monthsSafety phase (I)Oncology

Lower Limb Nonunion: NVD-003 Implant Study

We are testing a new 3D bone implant for adults with nonunion fractures in the lower limb. The study aims to evaluate its safety and effectiveness in promoting healing and improving quality of life.

Recalcitrant Lower Limb Nonunion1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and Traumatology

Head and Neck Cancer: TB0010 Treatment Study

We are evaluating the safety and tolerability of TB0010 in patients with head and neck squamous cell carcinoma. This study aims to understand how the drug is distributed in the body.

EGFR-Positive Head and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Oncology

Advanced Non-Small Cell Lung Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced non-small cell lung cancer. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Pancreatic Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced pancreatic cancer to see how well it works and how safe it is. This trial aims to evaluate its effectiveness and side effects compared to standard treatments.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Drug Resistance in Cancer: PET Imaging Study

We are exploring how a protein linked to drug resistance behaves in cancer patients using advanced imaging. This study aims to improve our understanding of treatment challenges in cancer care.

Healthy ParticipantsSafety phase (I)Neurology

Bone Infections: Clindamycin and Cefalexin Study

We are investigating how well clindamycin and cefalexin penetrate bone tissue in patients. This study aims to improve treatment options for bone infections.

Patients Undergoing Amputation SurgerySafety phase (I)Infectious DiseasesOrthopedics and Traumatology

Understanding ABCB1's Role in Metoclopramide Effects

We are studying how a gene may influence the way metoclopramide works in the brain for individuals taking this medication. This research aims to improve treatment outcomes for patients using metoclopramide.

Healthy ParticipantsSafety phase (I)Internal MedicineNeurology